Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis
- DOI
- 10.1007/s10549-009-0724-3
- Published
- 2010-01-08
- Container
- Breast Cancer Research and Treatment
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-009-0724-3,
title = {Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis},
author = {Myrthe P. P. van Herk-Sukel and Lonneke V. van de Poll-Franse and Adri C. Voogd and Grard A. P. Nieuwenhuijzen and Jan Willem W. Coebergh and Ron M. C. Herings},
year = {2010},
journal = {Breast Cancer Research and Treatment},
doi = {10.1007/s10549-009-0724-3},
url = {https://doi.org/10.1007/s10549-009-0724-3}
}RIS
TY - JOUR TI - Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis AU - Myrthe P. P. van Herk-Sukel AU - Lonneke V. van de Poll-Franse AU - Adri C. Voogd AU - Grard A. P. Nieuwenhuijzen AU - Jan Willem W. Coebergh AU - Ron M. C. Herings PY - 2010 JO - Breast Cancer Research and Treatment DO - 10.1007/s10549-009-0724-3 UR - https://doi.org/10.1007/s10549-009-0724-3 ER -
APA
Herk-Sukel, M. P. P. V., Poll-Franse, L. V. V. D., Voogd, A. C., Nieuwenhuijzen, G. A. P., Coebergh, J. W. W., & Herings, R. M. C. (2010). Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-009-0724-3
Source records
- crossref · retrieved 2026-11-08T16:23:18.044Z